Merck Says Hepatitis Pill Hampers HIV Drugs
February 13, 2012
Merck & Co.'s hepatitis C virus (HCV) treatment Victrelis (boceprevir) considerably lessens the effectiveness of some widely used HIV drugs, U.S. regulators and Merck recently announced.
02.09.2012; Randsell Pierson
FDA Drug Safety Communication: Important Drug Interactions Between Victrelis (Boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)